EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia

• Date:
  Antradienis, 30 Birželis 2026 , 14:00 - 18:00 Amsterdam time (CEST)
• Vieta:
  Online

Event summary

EMA is organising this workshop to have a multi-stakeholder's perspective on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia. This is in line with the clinical domain working party work plan for 2026.

The workshop outcomes will inform the next update of the Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia. 

The aims of the workshop are:

• to present the epidemiology and disease background in adults and children with immune thrombocytopenia, the current international treatment guidelines, the unmet medical need, and the overview of the authorised medicines/treatments for immune thrombocytopenia;
• to present the challenges in treatment/drug development from a clinicians', patients and regulator´s perspective with regards to study design, objectives and endpoints used in clinical trials.

Documents

Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia

Registration

Participants can register for online participation until 22 June via this link:

• EMA workshop on Challenges in drug development, regulation and clinical practice in immune thrombocytopenia